References

1. Grande, M.; Arigita, M.; Borobio, V.; Jimenez, J.M.; Fernandez, S.; Borrell, A. First-trimester detection of structural abnormalities and the role of aneuploidy markers. Ultrasound Obstet. Gynecol. 2012, 39, 157–163.
2. Brandt, J.S.; Cruz Ithier, M.A.; Rosen, T.; Ashkinadze, E. Advanced paternal age, infertility, and reproductive risks: A review of the literature. Prenat. Diagn. 2019, 39, 81–87.
3. Kagan, K.O.; Maier, V.; Sonek, J.; Abele, H.; Lüthgens, K.; Schmid, M.; Wagner, P.; Hoopmann, M. False-Positive Rate in First-Trimester Screening Based on Ultrasound and Cell-Free DNA versus First-Trimester Combined Screening with Additional Ultrasound Markers. Fetal Diagn. Ther. 2018, 45, 317–324.
4. Norton, M.E.; Jacobsson, B.; Swamy, G.K.; Laurent, L.C.; Ranzini, A.C.; Brar, H.; Tomlinson, M.W.; Pereira, L.; Spitz, J.L.; Hollemon, D.; et al. Cell-free DNA Analysis for Noninvasive Examination of Trisomy. N. Engl. J. Med. 2015, 372, 1589–1597.
5. Pescia, G.; Guex, N.; Iseli, C.; Brennan, L.; Osteras, M.; Xenarios, I.; Farinelli, L.; Conrad, B. Cell-free DNA testing of an extended range of chromoso-mal anomalies: Clinical experience with 6388 consecutive cases. Genet. Med. 2017, 19, 169–175.
6. Bianchi, D.W.; Wilkins-Haug, L. Integration of Noninvasive DNA Testing for Aneuploidy into Prenatal Care: What Has Happened Since the Rubber Met the Road? Clin. Chem. 2014, 60, 78–87.
7. Kostenko, E.; Chantraine, F.; Vandeweyer, K.; Schmid, M.; Lefevre, A.; Hertz, D.; Zelle, L.; Bartha, J.L.; Di Renzo, G.C. Clinical and Economic Impact of Adopting Noninvasive Prenatal Testing as a Primary Screening Method for Fetal Aneuploidies in the General Pregnancy Population. Fetal Diagn. Ther. 2018, 45, 413–423.
8. Gil, M.M.; Accurti, V.; Santacruz, B.; Plana, M.N.; Nicolaides, K.H. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: Updated meta-analysis: Cell-free DNA in screening for aneuploidies. Ultrasound Obstet. Gynecol. 2017, 50, 302–314.
9. Bianchi, D.W.; Parker, R.L.; Wentworth, J.; Madankumar, R.; Saffer, C.; Das, A.F.; Craig, J.A.; Chudova, D.I.; Devers, P.L.; Jones, K.W.; et al. DNA Sequencing versus Standard Prenatal Aneuploidy Screening. N. Engl. J. Med. 2014, 370, 799–808.
10. Iwarsson, E.; Conner, P. Detection rates and residual risk for a postnatal diagnosis of an atypical chromosome aberration fol-lowing combined first-trimester screening. Prenat. Diagn. 2020, 40, 852–859.
11. Petersen, O.B.; Vogel, I.; Ekelund, C.; Hyett, J.; Tabor, A.; Christiansen, M.; Farlie, R.; Hoseth, E.; Ibsen, M.H.; Jensen, H.S.; et al. Potential diagnostic consequences of applying non-invasive prenatal testing: Population-based study from a country with existing first-trimester screening: What is missed by NIPT? Ultrasound Obstet. Gynecol. 2014, 43, 265–271.
12. Salomon, L.J.; Alfirevic, Z.; Raine-Fenning, N.J.; Timor-Tritsch, I.; Seshadri, S. Practice Guidelines: Performance of first-trimester fetal ultrasound scan: ISUOG Guidelines. Ultrasound Obstet. Gynecol. 2013, 41, 102–113.
13. Zalel, Y. Non-invasive prenatal testing—It’s all a matter of timing. Ultrasound Obstet. Gynecol. 2015, 45, 115–116.
14. Bardi, F.; Bosschieter, P.; Verheij, J.; Go, A.; Haak, M.; Bekker, M.; Sikkel, E.; Coumans, A.; Pajkrt, E.; Bilardo, C. Is there still a role for nuchal translucency measurement in the changing paradigm of first trimester screening? Prenat. Diagn. 2020, 40, 197–205.
15. Brown, I.; Fernando, S.; Menezes, M.; Costa, F.D.S.; Ramkrishna, J.; Meagher, S.; Rolnik, D.L. The importance of ultrasound preceding cell-free DNA screening for fetal chromosomal abnormalities. Prenat. Diagn. 2020, 40, 1439–1446.
16. Guseh, S.H. Noninvasive prenatal testing: From aneuploidy to single genes. Qual. Life Res. 2020, 139, 1141–1148.
17. Baer, R.J.; Norton, M.E.; Shaw, G.M.; Flessel, M.C.; Goldman, S.; Currier, R.J.; Jelliffe-Pawlowski, L.L. Risk of selected structural abnormalities in infants after increased nuchal translucency measurement. Am. J. Obstet. Gynecol. 2014, 211, 675.e1–675.e19.
18. Sotiriadis, A.; Papatheodorou, S.; Eleftheriades, M.; Makrydimas, G. Nuchal translucency and major congenital heart defects in fetuses with normal karyotype: A meta-analysis: NT and cardiac defects. Ultrasound Obstet. Gynecol. 2013, 42, 383–389.
19. Syngelaki, A.; Hammami, A.; Bower, S.; Zidere, V.; Akolekar, R.; Nicolaides, K.H. Diagnosis of fetal non-chromosomal abnormalities on routine ultrasound examination at 11–13 weeks’ gestation. Ultrasound Obstet. Gynecol. 2019, 54, 468–476.
20. Kagan, K.O.; Staboulidou, I.; Syngelaki, A.; Cruz, J.; Nicolaides, K.H. The 11–13-week scan: Diagnosis and outcome of holoprosen-cephaly, exomphalos and megacystis. Ultrasound Obstet. Gynecol. 2010, 36, 10–14.
21. Meler, E.; Sisterna, S.; Borrell, A. Genetic syndromes associated with isolated fetal growth restriction. Prenat. Diagn. 2019, 40, 432–446.
22. Borrell, A.; Grande, M.; Meler, E.; Sabrià, J.; Mazarico, E.; Muñoz, A.; Rodriguez-Revenga, L.; Badenas, C.; Figueras, F. Genomic Microarray in Fetuses with Early Growth Re-striction: A Multicenter Study. Fetal Diagn. Ther. 2017, 42, 174–180.
23. Wapner, R.J.; Martin, C.L.; Levy, B.; Ballif, B.C.; Eng, C.M.; Zachary, J.M.; Savage, M.; Platt, L.D.; Saltzman, D.; Grobman, W.A.; et al. Chromosomal microarray versus karyotyping for pre-natal diagnosis. N. Engl. J. Med. 2012, 367, 2175–2184.
24. Grande, M.; Jansen, F.A.R.; Blumenfeld, Y.J.; Fisher, A.; Odibo, A.O.; Haak, M.C.; Borrell, A. Genomic microarray in fetuses with increased nuchal translucency and normal karyotype: A systematic review and meta-analysis: Microarray and increased nuchal translucency. Ultrasound Obstet. Gynecol. 2015, 46, 650–658.
25. Hillman, S.C.; McMullan, D.J.; Hall, G.; Togneri, F.S.; James, N.; Maher, E.J.; Meller, C.H.; Williams, D.; Wapner, R.J.; Maher, E.R.; et al. Use of prenatal chromosomal microarray: Prospective cohort study and systematic review and meta-analysis: Prenatal CMA: Cohort study and systematic review. Ultrasound Obstet. Gynecol. 2013, 41, 610–620.
26. Eggermann, T. Prenatal Detection of Uniparental Disomies (UPD): Intended and Incidental Finding in the Era of Next Generation Genomics. Genes 2020, 11, 1454.
27. Levy, B.; Wapner, R. Prenatal diagnosis by chromosomal microarray analysis. Fertil. Steril. 2018, 109, 201–212.
28. Donnelly, J.C.; Platt, L.D.; Rebarber, A.; Zachary, J.; Grobman, W.A.; Wapner, R.J. Association of Copy Number Variants With Spe-cific Ultrasonographically Detected Fetal Anomalies. Obstet. Gynecol. 2014, 124, 83–90.
29. Jansen, F.A.R.; Blumenfeld, Y.J.; Fisher, A.; Cobben, J.M.; Odibo, A.O.; Borrell, A.; Haak, M.C. Array comparative genomic hybridization and fetal congenital heart defects: A systematic review and meta-analysis. Ultrasound Obstet. Gynecol. 2014, 45, 27–35.
30. Berger, S.; Cheung, S.; Maliszewski, K.; Patel, A.; Pursley, A.; Lenchner, E.; Bacino, C.; Beaudet, A.; Divon, M.; Bornstein, E. Universal Prenatal Chromosomal Microarray Analysis: Additive Value and Clinical Dilemmas in Fetuses with a Normal Karyotype. Am. J. Perinatol. 2016, 34, 340–348.
31. Lund, I.C.B.; Christensen, R.; Petersen, O.B.; Vogel, I.; Vestergaard, E.M. Chromosomal microarray in fetuses with increased nuchal translucency. Ultrasound Obstet. Gynecol. 2014, 45, 95–100.
32. Maya, I.; Yacobson, S.; Kahana, S.; Yeshaya, J.; Tenne, T.; Agmon-Fishman, I.; Cohen-Vig, L.; Shohat, M.; Basel-Vanagaite, L.; Sharony, R. Cut-off value of nuchal translucency as indica-tion for chromosomal microarray analysis: NT and CMA. Ultrasound Obstet. Gynecol. 2017, 50, 332–335.
33. Srebniak, M.I.; De Wit, M.C.; Diderich, K.E.M.; Govaerts, L.C.P.; Joosten, M.; Knapen, M.F.C.M.; Bos, M.J.; Looye-Bruinsma, G.A.G.; Koningen, M.; Go, A.T.J.I.; et al. Enlarged NT (≥3.5 mm) in the first trimester—Not all chromosome aberrations can be detected by NIPT. Mol. Cytogenet. 2016, 9, 69.
34. Xue, S.; Yan, H.; Chen, J.; Li, N.; Wang, J.; Liu, Y.; Zhang, H.; Li, S.; Zhang, W.; Chen, D.; et al. Genetic Examination for Fetuses with Increased Fetal Nuchal Translucency by Genomic Technology. Cytogenet. Genome Res. 2020, 160, 57–62.
35. Bornstein, E.; Gulersen, M.; Krantz, D.; Cheung, S.W.; Maliszewski, K.; Divon, M.Y. Microarray analysis: First-trimester maternal serum free β-hCG and the risk of significant copy number variants. Prenat. Diagn. 2018, 38, 971–978.
36. Abou Tayoun, A.N.; Spinner, N.B.; Rehm, H.L.; Green, R.C.; Bianchi, D.W. Prenatal DNA Sequencing: Clinical, Counseling, and Diagnostic Laboratory Considerations: Prenatal DNA sequencing: Clinical and laboratory considerations. Prenat. Diagn. 2018, 38, 26–32.
37. Borrell, A. A new comprehensive paradigm for prenatal diagnosis: Seeing the forest through the trees. Ultrasound Obstet. Gynecol. 2018, 52, 563–568.
38. Warr, A.; Robert, C.; Hume, D.; Archibald, A.; Deeb, N.; Watson, M. Exome Sequencing: Current and Future Perspectives. G3 Genes Genomes Genet. 2015, 5, 1543–1550.
39. Lefkowitz, R.B.; Tynan, J.A.; Liu, T.; Wu, Y.; Mazloom, A.R.; Almasri, E.; Hogg, G.; Angkachatchai, V.; Zhao, C.; Grosu, D.S.; et al. Clinical validation of a noninvasive prenatal test for genomewide detection of fetal copy number variants. Am. J. Obstet. Gynecol. 2016, 215, 227.e1–227.e16.
40. Chen, Y.; Yu, Q.; Mao, X.; Lei, W.; He, M.; Lu, W. Noninvasive prenatal testing for chromosome aneuploidies and subchromosomal microdeletions/microduplications in a cohort of 42,910 single pregnancies with different clinical features. Hum. Genom. 2019, 13, 1–8.
41. Martin, K.; Kantor, V.; Dhamankar, R.; Valenti, L.; Lyons, D.; Trefogli, M.; Balosbalos, I.; Kao, C.; Hakonarson, H.; Martin, K.A. Validation of SNP-based Noninvasive Prenatal Screening Test to Detect Maternal X Chromosome Abnormalities. Eur. J. Hum. Genet. 2019, 27, 1192.
42. Grati, F.R.; Gross, S.J. Noninvasive screening by cell-free DNA for 22q11.2 deletion: Benefits, limitations, and challenges. Prenat. Diagn. 2019, 39, 70–80.
43. Bianchi, D.W. Turner syndrome: New insights from prenatal genomics and transcriptomics. Am. J. Med. Genet. Part. C Semin. Med. Genet. 2019, 181, 29–33.
44. Brison, N.; Van Den Bogaert, K.; Dehaspe, L.; van den Oever, J.M.E.; Janssens, K.; Blaumeiser, B.; Peeters, H.; Van Esch, H.; Van Buggenhout, G.; Vogels, A.; et al. Accuracy and clinical value of maternal incidental findings during noninvasive prenatal testing for fetal aneuploidies. Genet. Med. 2017, 19, 306–313.
45. American College of Obstetricians and Gynecologists. Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin Summary, Number 226. Obstet. Gynecol. 2020, 136, 859–867.
46. Kozlowski, P.; Burkhardt, T.; Gembruch, U.; Gonser, M.; Kähler, C.; Kagan, K.-O.; Von Kaisenberg, C.; Klaritsch, P.; Merz, E.; Steiner, H.; et al. DEGUM, ÖGUM, SGUM and FMF Germany Recommendations for the Implementation of First-Trimester Screening, Detailed Ultrasound, Cell-Free DNA Screening and Diagnostic Procedures. Ultraschall Med. Eur. J. Ultrasound 2018, 40, 176–193.
47. Finning, K.M.; Chitty, L.S. Non-invasive fetal sex determination: Impact on clinical practice. Semin. Fetal Neonatal Med. 2008, 13, 69–75.
48. Devaney, S.A.; Palomaki, G.E.; Scott, J.A.; Bianchi, D.W. Noninvasive Fetal Sex Determination Using Cell-Free Fetal DNA. JAMA 2011, 306, 627–636.
49. Hill, M.; Finning, K.; Martin, P.; Hogg, J.; Meaney, C.; Norbury, G.; Daniels, G.; Chitty, L.S. Non-invasive prenatal determination of fetal sex: Translating research into clinical practice. Clin. Genet. 2011, 80, 68–75.
50. Hayward, J.; Chitty, L.S. Beyond screening for chromosomal abnormalities: Advances in non-invasive diagnosis of single gene disorders and fetal exome sequencing. Semin. Fetal Neonatal Med. 2018, 23, 94–101.
51. Shaw, J.; Scotchman, E.; Chandler, N.; Chitty, L.S. Preimplantation Genetic Testing: Non-invasive prenatal testing for aneuploidy, copy-number variants and single-gene disorders. Reproduction 2020, 160, A1–A11.
52. Jenkins, L.A.; Deans, Z.C.; Lewis, C.; Allen, S. Delivering an accredited non-invasive prenatal diagnosis service for monogenic disorders and recommendations for best practice: Delivering an accredited non-invasive prenatal diagnosis service. Prenat. Diagn. 2018, 38, 44–51.
53. Zhang, J.; Li, J.; Saucier, J.B.; Feng, Y.; Jiang, Y.; Sinson, J.; McCombs, A.K.; Schmitt, E.S.; Peacock, S.; Chen, S.; et al. Non-invasive prenatal sequencing for multiple Mendelian monogenic disorders using circulating cell-free fetal DNA. Nat. Med. 2019, 25, 439–447.
54. Tsao, D.S.; Silas, S.; Landry, B.P.; Itzep, N.P.; Nguyen, A.B.; Greenberg, S.; Kanne, C.K.; Sheehan, V.A.; Sharma, R.; Shukla, R.; et al. A novel high-throughput molecular counting method with single base-pair resolution enables accurate single-gene NIPT. Sci. Rep. 2019, 9, 1–14.
55. Yang, L.; Wu, Y.; Hu, Z.; Zhang, H.; Pu, D.; Yan, H.; Zhang, S.; Jiang, H.; Liu, Q.; Yuan, Y.; et al. Simultaneous detection of fetal aneuploidy, de novo FGFR3 mutations and paternally derived β-thalassemia by a novel method of noninvasive prenatal testing. Prenat. Diagn. 2021, 41, 440–448.
56. Beaudet, A.L. Using fetal cells for prenatal diagnosis: History and recent progress. Am. J. Med. Genet. Part C Semin. Med. Genet. 2016, 172, 123–127.
57. Vossaert, L.; Wang, Q.; Salman, R.; Zhuo, X.; Qu, C.; Henke, D.; Seubert, R.; Chow, J.; U’ren, L.; Enright, B.; et al. Reliable detection of subchromosomal deletions and duplications using cell-based noninvasive prenatal testing. Prenat. Diagn. 2018, 38, 1069–1078.
58. Pfeifer, I.; Benachi, A.; Saker, A.; Bonnefont, J.-P.; Mouawia, H.; Broncy, L.; Frydman, R.; Brival, M.; Lacour, B.; Dachez, R.; et al. Cervical trophoblasts for non-invasive single-cell genotyping and prenatal diagnosis. Placenta 2016, 37, 56–60.
59. Jeppesen, L.D.; Hatt, L.; Singh, R.; Ravn, K.; Kølvraa, M.; Schelde, P.; Uldbjerg, N.; Vogel, I.; Lildballe, D.L. Cell-based non-invasive prenatal diagnosis in a pregnancy at risk of cystic fibrosis. Prenat. Diagn. 2020, 41, 234–240.
60. Vestergaard, E.M.; Singh, R.; Schelde, P.; Hatt, L.; Ravn, K.; Christensen, R.; Lildballe, D.L.; Petersen, O.B.; Uldbjerg, N.; Vogel, I. On the road to replacing invasive testing with cell-based NIPT: Five clinical cases with aneuploidies, microduplication, unbalanced structural rearrangement, or mosaicism. Prenat. Diagn. 2017, 37, 1120–1124.
61. Breman, A.M.; Chow, J.C.; U’Ren, L.; Normand, E.A.; Qdaisat, S.; Zhao, L.; Henke, D.M.; Chen, R.; Shaw, C.A.; Jackson, L.; et al. Evidence for feasibility of fetal trophoblastic cell-based noninvasive prenatal testing. Prenat. Diagn. 2016, 36, 1009–1019.
62. Van der Meij, K.R.M.; Sistermans, E.A.; Macville, M.V.E.; Stevens, S.J.C.; Bax, C.J.; Bekker, M.N.; Bilardo, C.M.; Boon, E.M.; Boter, M.; Diderich, K.E.; et al. TRIDENT-2: National Implementation of Genome-wide Non-invasive Prenatal Testing as a First-Tier Screening Test in the Netherlands. Am. J. Hum. Genet. 2019, 105, 1091–1101.
63. Viuff, M.H.; Stochholm, K.; Uldbjerg, N.; Nielsen, B.B.; Gravholt, C.H. The Danish Fetal Medicine Study Group Only a minority of sex chromosome abnormalities are detected by a national prenatal screening program for Down syndrome. Hum. Reprod. 2015, 30, 2419–2426.
64. Sagaser, K.G.; Stevens, B.; Davis, J.; Northrup, H.; Ramdaney, A. Close but not quite: Two cases of sex chromosome aneuploidies outside the scope of cell free DNA screening. Prenat. Diagn. 2018, 38, 617–619.
65. Ramdaney, A.; Hoskovec, J.; Harkenrider, J.; Soto, E.; Murphy, L. Clinical experience with sex chromosome aneuploidies detected by noninvasive prenatal testing (NIPT): Accuracy and patient decision-making. Prenat. Diagn. 2018, 38, 841–848.
66. Deng, C.; Zhu, Q.; Liu, S.; Liu, J.; Bai, T.; Jing, X.; Xia, T.; Liu, Y.; Cheng, J.; Li, Z.; et al. Clinical application of noninvasive prenatal screening for sex chromosome aneuploidies in 50,301 pregnancies: Initial experience in a Chinese hospital. Sci. Rep. 2019, 9, 7767.
67. Grati, F.R. Chromosomal Mosaicism in Human Feto-Placental Development: Implications for Prenatal Diagnosis. J. Clin. Med. 2014, 3, 809–837.
68. Malvestiti, F.; Agrati, C.; Grimi, B.; Pompilii, E.; Izzi, C.; Martinoni, L.; Gaetani, E.; Liuti, M.R.; Trotta, A.; Maggi, F.; et al. Interpreting mosaicism in chorionic villi: Results of a monocentric series of 1001 mosaics in chorionic villi with follow-up amniocentesis: Interpreting mosaicism in chorionic villi. Prenat. Diagn. 2015, 35, 1117–1127.
69. Zhang, B.; Zhou, Q.; Chen, Y.; Shi, Y.; Zheng, F.; Liu, J.; Yu, B. High false-positive non-invasive prenatal screening results for sex chromosome abnormalities: Are maternal factors the culprit? Prenat. Diagn. 2020, 40, 463–469.
70. Wang, Y.; Chen, Y.; Tian, F.; Zhang, J.; Song, Z.; Wu, Y.; Han, X.; Hu, W.; Ma, D.; Cram, D.; et al. Maternal Mosaicism Is a Significant Contributor to Discordant Sex Chromosomal Aneuploidies Associated with Noninvasive Prenatal Testing. Clin. Chem. 2014, 60, 251–259.
71. Sandow, R.; Scott, F.P.; Schluter, P.J.; Rolnik, D.L.; Menezes, M.; Nisbet, D.; McLennan, A.C. Increasing maternal age is not a significant cause of false-positive results for monosomy X in non-invasive prenatal testing. Prenat. Diagn. 2020, 40, 1466–1473.
72. Levy, B.; Burnside, R.D. Are all chromosome microarrays the same? What clinicians need to know. Prenat. Diagn. 2019, 39, 157–164.
73. Srebniak, M.I.; Joosten, M.; Knapen, M.F.C.; Arends, L.R.; Polak, M.; van Veen, S.; Go, A.T.J.I.; Van Opstal, D. Frequency of submicroscopic chromosomal aberrations in pregnancies without increased risk for structural chromosomal aberrations: Systematic review and meta-analysis. Ultrasound Obstet. Gynecol. 2018, 51, 445–452.
74. Gurbich, T.A.; Ilinsky, V.V. ClassifyCNV: A tool for clinical annotation of copy-number variants. Sci. Rep. 2020, 10, 1–7.
75. Redon, R.; Ishikawa, S.; Fitch, K.R.; Feuk, L.; Perry, G.H.; Andrews, T.D.; Fiegler, H.; Shapero, M.H.; Carson, A.R.; Chen, W.; et al. Global variation in copy number in the human genome. Nature 2006, 444, 444–454.
76. Riggs, E.R.; Andersen, E.F.; Cherry, A.M.; Kantarci, S.; Kearney, H.; Patel, A.; Raca, G.; Ritter, D.I.; South, S.T.; Thorland, E.C.; et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: A joint consensus recommendation of the American College of Medical Ge-netics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet. Med. 2020, 22, 245–257.
77. Romero, S.T.; Geiersbach, K.B.; Paxton, C.N.; Rose, N.C.; Schisterman, E.F.; Branch, D.W.; Silver, R.M. Differentiation of genetic abnormalities in early pregnancy loss. Ultrasound Obstet. Gynecol. 2015, 45, 89–94.
78. Advani, H.V.; Barrett, A.N.; Evans, M.I.; Choolani, M. Challenges in non-invasive prenatal screening for sub-chromosomal copy number variations using cell-free DNA. Prenat. Diagn. 2017, 37, 1067–1075.
79. Lo, K.K.; Karampetsou, E.; Boustred, C.; McKay, F.; Mason, S.; Hill, M.; Plagnol, V.; Chitty, L.S. Limited Clinical Utility of Non-invasive Prenatal Testing for Subchromosomal Abnormalities. Am. J. Hum. Genet. 2016, 98, 34–44.
80. Hu, H.; Wang, L.; Wu, J.; Zhou, P.; Fu, J.; Sun, J.; Cai, W.; Liu, H.; Yang, Y. Noninvasive prenatal testing for chromosome aneuploidies and subchromo-somal microdeletions/microduplications in a cohort of 8141 single pregnancies. Hum. Genom. 2019, 13, 14.
81. Srinivasan, A.; Bianchi, D.W.; Huang, H.; Sehnert, A.J.; Rava, R.P. Noninvasive Detection of Fetal Subchromosome Abnormalities via Deep Sequencing of Maternal Plasma. Am. J. Hum. Genet. 2013, 92, 167–176.
82. Weise, A.; Mrasek, K.; Klein, E.; Mulatinho, M.; Llerena, J.C.; Hardekopf, D.; Pekova, S.; Bhatt, S.; Kosyakova, N.; Liehr, T.; et al. Microdeletion and Microduplication Syndromes. J. Histochem. Cytochem. 2012, 60, 346–358.
83. Wapner, R.J.; Babiarz, J.E.; Levy, B.; Stosic, M.; Zimmermann, B.; Sigurjonsson, S.; Wayham, N.; Ryan, A.; Banjevic, M.; Lacroute, P.; et al. Expanding the scope of noninvasive prenatal testing: Detection of fetal microdeletion syndromes. Am. J. Obstet. Gynecol. 2015, 212, 332.e1–332.e9.
84. Martin, K.; Iyengar, S.; Kalyan, A.; Lan, C.; Simon, A.L.; Stosic, M.; Kobara, K.; Ravi, H.; Truong, T.; Ryan, A.; et al. Clinical experience with a single-nucleotide polymorphism-based non-invasive prenatal test for five clinically significant microdeletions. Clin. Genet. 2018, 93, 293–300.
85. Helgeson, J.; Wardrop, J.; Boomer, T.; Almasri, E.; Paxton, W.B.; Saldivar, J.S.; Dharajiya, N.; Monroe, T.J.; Farkas, D.H.; Grosu, D.S.; et al. Clinical outcome of subchromosomal events detected by whole-genome noninvasive prenatal testing. Prenat. Diagn. 2015, 35, 999–1004.
86. Petersen, A.K.; Cheung, S.W.; Smith, J.L.; Bi, W.; Ward, P.A.; Peacock, S.; Braxton, A.; Van Den Veyver, I.B.; Breman, A.M. Positive predictive value estimates for cell-free noninvasive prenatal screening from data of a large referral genetic diagnostic laboratory. Am. J. Obstet. Gynecol. 2017, 217, 691.e1–691.e6.
87. Kagan, K.O.; Hoopmann, M.; Pfaff, T.; Prodan, N.; Wagner, P.; Schmid, M.; Dufke, A.; Mau-Holzmann, U.; Brucker, S.; Marcato, L.; et al. First Trimester Screening for Common Trisomies and Microdeletion 22q11.2 Syndrome Using Cell-Free DNA: A Prospective Clinical Study. Fetal Diagn. Ther. 2020, 47, 841–851.
88. Dondorp, W.; De Wert, G.; Bombard, Y.; Bianchi, D.W.; Bergmann, C.; Borry, P.; Chitty, L.S.; Fellmann, F.; Forzano, F.; Hall, A.; et al. Non-invasive prenatal testing for aneuploidy and beyond: Challenges of responsible innovation in prenatal screening. Summary and recommendations. Eur. J. Hum. Genet. 2015, 23, 1438–1450.
89. Benn, P.; Malvestiti, F.; Grimi, B.; Maggi, F.; Simoni, G.; Grati, F.R. Rare autosomal trisomies: Comparison of detection through cell-free DNA analysis and direct chromosome preparation of chorionic villus samples. Ultrasound Obstet. Gynecol. 2019, 54, 458–467.
90. Yaron, Y.; Pauta, M.; Badenas, C.; Soler, A.; Borobio, V.; Illanes, C.; Paz-Y-Miño, F.; Martinez-Portilla, R.; Borrell, A. Maternal plasma genome-wide cell-free DNA can detect fetal aneuploidy in early and recurrent pregnancy loss and can be used to direct further workup. Hum. Reprod. 2020, 35, 1222–1229.
91. Pauta, M.; Grande, M.; Rodriguez-Revenga, L.; Kolomietz, E.; Borrell, A. Added value of chromosomal microarray analysis over karyotyping in early pregnancy loss: Systematic review and meta-analysis. Ultrasound Obstet. Gynecol. 2018, 51, 453–462.
92. Zheng, J.; Lu, H.; Li, M.; Guan, Y.; Yang, F.; Xu, M.; Dong, J.; Zhang, Q.; An, N.; Zhou, Y. The Clinical Utility of Non-invasive Prenatal Testing for Pregnant Women with Different Diagnostic Indications. Front. Genet. 2020, 11, 624.
93. Eggermann, T.; Soellner, L.; Buiting, K.; Kotzot, D. Mosaicism and uniparental disomy in prenatal diagnosis. Trends Mol. Med. 2015, 21, 77–87.
94. Scott, F.; Bonifacio, M.; Sandow, R.; Ellis, K.; Smet, M.-E.; McLennan, A. Rare autosomal trisomies: Important and not so rare. Prenat. Diagn. 2018, 38, 765–771.
95. Gou, L.; Fang, Y.; Wang, N.; Zhang, M.; Liu, T.; Wang, Y.; Hu, S.; Zhang, Y.; Wu, Q.; Wang, Y.; et al. Clinical management of pregnancies with positive screening results for rare autosomal aneuploidies at a single center. J. Int. Med. Res. 2020, 48.
96. Benn, P.; Grati, F.R. Genome-wide non-invasive prenatal screening for all cytogenetically visible imbalances. Ultrasound Obstet. Gynecol. 2018, 51, 429–433.
97. Imbert-Bouteille, M.; Chiesa, J.; Gaillard, J.-B.; Dorvaux, V.; Altounian, L.; Gatinois, V.; Mousty, E.; Finge, S.; Bourquard, P.; Vermeesch, J.R.; et al. An incidental finding of maternal multiple myeloma by non invasive prenatal testing. Prenat. Diagn. 2017, 37, 1257–1260.
98. Benn, P.; Plon, S.E.; Bianchi, D.W. Current Controversies in Prenatal Diagnosis 2: NIPT results suggesting maternal cancer should always be disclosed. Prenat. Diagn. 2018, 39, 339–343.
99. Le Caignec, C. Detection of genomic imbalances by array based comparative genomic hybridisation in fetuses with multiple malformations. J. Med. Genet. 2005, 42, 121–128.
100. Savage, M.S.; Mourad, M.J.; Wapner, R.J. Evolving applications of microarray analysis in prenatal diagnosis. Curr. Opin. Obstet. Gynecol. 2011, 23, 103–108.
101. Society for Maternal-Fetal Medicine (SMFM); Dugoff, L.; Norton, M.E.; Kuller, J.A. The use of chromosomal microarray for prenatal diagnosis. Am. J. Obstet. Gynecol. 2016, 215, B2–B9.
102. Maya, I.; Sharony, R.; Yacobson, S.; Kahana, S.; Yeshaya, J.; Tenne, T.; Agmon-Fishman, I.; Cohen-Vig, L.; Goldberg, Y.; Berger, R.; et al. When genotype is not predictive of phenotype: Implica-tions for genetic counseling based on 21,594 chromosomal microarray analysis examinations. Genet. Med. 2018, 20, 128–131.
103. Van den Veyver, I.B.; Eng, C.M. Genome-Wide Sequencing for Prenatal Detection of Fetal Single-Gene Disorders. Cold Spring Harb. Perspect. Med. 2015, 5, a023077.
104. Abou Tayoun, A.; Mason-Suares, H. Considerations for whole exome sequencing unique to prenatal care. Hum. Genet. 2020, 139, 1149–1159.
105. Best, S.; Wou, K.; Vora, N.; Van der Veyver, I.B.; Wapner, R.; Chitty, L.S. Promises, pitfalls and practicalities of prenatal whole exo-me sequencing: Promises and pitfalls of prenatal whole exome sequencing. Prenat. Diagn. 2018, 38, 10–19.
106. Lord, J.; McMullan, D.J.; Eberhardt, R.Y.; Rinck, G.; Hamilton, S.J.; Quinlan-Jones, E.; Prigmore, E.; Keelagher, R.; Best, S.K.; Carey, G.K.; et al. Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): A cohort study. Lancet 2019, 393, 747–757.
107. Drury, S.; Williams, H.; Trump, N.; Boustred, C.; Gene, G.O.S.; Lench, N.; Scott, R.H.; Chitty, L.S. Exome sequencing for prenatal diagnosis of fetuses with sonographic abnormalities: Exome sequencing for prenatal diagnosis. Prenat. Diagn. 2015, 35, 1010–1017.
108. The International Society for Prenatal Diagnosis; The Society for Maternal and Fetal Medicine; The Perinatal Quality Foundation. Joint Position Statement from the International Society for Prenatal Diagnosis (ISPD), the Society for Maternal Fetal Medicine (SMFM), and the Perinatal Quality Foundation (PQF) on the use of genome-wide sequencing for fetal diagnosis: Genomewide sequencing for fetal diagnosis. Prenat. Diagn. 2018, 38, 6–9.